At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
10% VDA-1102 +1 moredrug
Likely dose
10% VDA-1102 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
In Brief
A Phase 2 clinical trial evaluating 10% VDA-1102 and 20% VDA-1102 for Actinic Keratosis. Completed, enrolled 83 participants across 1 site.
Detailed Summary
This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days). This study has no placebo and the subjects enrolled in the study will know exactly what they are receiving. The objectives of the study are to evaluate the safety and benefit of these two strengths.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
CollaboratorsTherapeutics, Inc., PharPoint Research, Inc., Medistat Ltd., Israel
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedMay 29, 2018
Enrollment StartMay 23, 2018
Primary CompletionDec 10, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.1 years ago
Interventions
10% VDA-1102drug
200 mg twice-daily for 12 weeks
20% VDA-1102drug
200 mg once-daily for 12 weeks